Sagentia completes alpha prototype of PathoGenetix's microbial genotyping system.
M2 PHARMA-May 10, 2013-Sagentia completes alpha prototype of PathoGenetix's microbial genotyping system(C)2013 M2 COMMUNICATIONS
10 May 2013 - US technology and product development company Sagentia Inc unveiled yesterday it had finished the initial alpha prototype development of the microbial genotyping system, Resolution, it has been developing for PathoGenetix Inc.
Sagentia works on combining of two initial bread board systems into a single system with a smaller footprint, under a technology and product development deal with PathoGenetix.
The Resolution system was developed on the basis of PathoGenetix's proprietary Genome Sequence Scanning (GSS) technology, designed to identify bio-threat pathogens in environmental samples. The GSS technique utilised in Resolution automates the isolation and analysis of single DNA molecules from complex mixtures, thus eliminating the necessity for a pure culture isolate. It also provides molecular serotype and strain type information for target bacteria in five hours.
Sagentia was initially involved in concept validation and voice of the customer analysis, thus helping PathoGenetix outline its go-to-market strategy for the GSS technology. Then, the focus has shifted on the development of the architecture and delivery of the electro-mechanical and electro-optical aspects which will enable the technique to be launched.
((Comments on this story may be sent to email@example.com))